## Miguel A Gonzalez-Gay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6187873/publications.pdf

Version: 2024-02-01

612 papers

27,928 citations

88 h-index 9589 142

634 all docs

634 docs citations

634 times ranked

24093 citing authors

g-index

#	Article	IF	CITATIONS
1	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	27.8	1,974
2	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature Genetics, 2013, 45, 730-738.	21.4	699
3	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	21.4	558
4	Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis and Rheumatism, 2009, 61, 1454-1461.	6.7	460
5	Leptin in the interplay of inflammation, metabolism and immune system disorders. Nature Reviews Rheumatology, 2017, 13, 100-109.	8.0	371
6	Permanent visual loss and cerebrovascular accidents in giant cell arteritis: Predictors and response to treatment. Arthritis and Rheumatism, 1998, 41, 1497-1504.	6.7	367
7	Henochâ€6chönlein purpura in adulthood and childhood. Two different expressions of the same syndrome. Arthritis and Rheumatism, 1997, 40, 859-864.	6.7	365
8	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics, 2010, 42, 426-429.	21.4	351
9	Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients. Medicine (United States), 2000, 79, 283-292.	1.0	333
10	HLA–DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 57, 125-132.	6.7	312
11	Obesity, Fat Mass and Immune System: Role for Leptin. Frontiers in Physiology, 2018, 9, 640.	2.8	284
12	Rheumatoid Arthritis: A Disease Associated with Accelerated Atherogenesis. Seminars in Arthritis and Rheumatism, 2005, 35, 8-17.	3.4	282
13	Association of a functional singleâ€nucleotide polymorphism of <i>PTPN22</i> , encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 219-224.	6.7	275
14	Giant Cell Arteritis. Medicine (United States), 2005, 84, 269-276.	1.0	256
15	Henoch-Schönlein Purpura in Children from Northwestern Spain. Medicine (United States), 2001, 80, 279-290.	1.0	235
16	High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis and Rheumatism, 2007, 57, 1074-1080.	6.7	220
17	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. Nature Communications, 2015, 6, 7146.	12.8	220
18	Carotid Intima-Media Thickness Predicts the Development of Cardiovascular Events in Patients with Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2009, 38, 366-371.	3.4	211

#	Article	IF	Citations
19	Increased Prevalence of Severe Subclinical Atherosclerotic Findings in Long-Term Treated Rheumatoid Arthritis Patients Without Clinically Evident Atherosclerotic Disease. Medicine (United States), 2003, 82, 407-413.	1.0	207
20	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genetics, 2011, 7, e1002178.	3.5	201
21	Aortic Aneurysm and Dissection in Patients With Biopsy-Proven Giant Cell Arteritis From Northwestern Spain. Medicine (United States), 2004, 83, 335-341.	1.0	200
22	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.	5.8	197
23	Polymyalgia rheumatica. Lancet, The, 2017, 390, 1700-1712.	13.7	196
24	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 48-54.	0.9	194
25	Biopsy-negative giant cell arteritis: Clinical spectrum and predictive factors for positive temporal artery biopsy. Seminars in Arthritis and Rheumatism, 2001, 30, 249-256.	3.4	193
26	Systemic Vasculitis in Adults in Northwestern Spain, 1988-1997: Clinical and Epidemiologic Aspects. Medicine (United States), 1999, 78, 292-308.	1.0	191
27	Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor $\hat{l}_{\pm}$ antibody. Arthritis and Rheumatism, 2004, 51, 447-450.	6.7	191
28	The epidemiology of the primary systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference definitions. Arthritis and Rheumatism, 2003, 49, 388-393.	6.7	190
29	Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Annals of the Rheumatic Diseases, 2014, 73, 722-727.	0.9	190
30	Strokes at Time of Disease Diagnosis in a Series of 287 Patients With Biopsy-Proven Giant Cell Arteritis. Medicine (United States), 2009, 88, 227-235.	1.0	189
31	High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. Journal of Rheumatology, 2005, 32, 1219-23.	2.0	187
32	Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis and Rheumatism, 2007, 57, 287-293.	6.7	185
33	Could HLA-DRB1 be the protective locus in rheumatoid arthritis?. Trends in Immunology, 1995, 16, 274-278.	7.5	183
34	Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	6.2	182
35	EPIDEMIOLOGY OF THE VASCULITIDES. Rheumatic Disease Clinics of North America, 2001, 27, 729-749.	1.9	181
36	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Annals of the Rheumatic Diseases, 2020, 79, 1544-1549.	0.9	173

#	Article	IF	CITATIONS
37	Henoch-Schönlein purpura in children and adults: Clinical differences in a defined population. Seminars in Arthritis and Rheumatism, 2002, 32, 149-156.	3.4	170
38	Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Seminars in Arthritis and Rheumatism, 2004, 33, 289-293.	3.4	170
39	Giant Cell Arteritis in Northwestern Spain. Medicine (United States), 2007, 86, 61-68.	1.0	168
40	Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2002, 31, 355-360.	3.4	164
41	HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. American Journal of Medicine, 2003, 114, 647-652.	1.5	160
42	Influence of Traditional Risk Factors of Atherosclerosis in the Development of Severe Ischemic Complications in Giant Cell Arteritis. Medicine (United States), 2004, 83, 342-347.	1.0	157
43	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. American Journal of Human Genetics, 2014, 94, 522-532.	6.2	156
44	Rheumatoid arthritis and metabolic syndrome. Nature Reviews Rheumatology, 2014, 10, 691-696.	8.0	154
45	Giant Cell Arteritis. Medicine (United States), 2005, 84, 277-290.	1.0	149
46	Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Seminars in Arthritis and Rheumatism, 2003, 33, 38-48.	3.4	146
47	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
48	Protection against anti–citrullinated protein antibody–positive rheumatoid arthritis is predominantly associated with HLA–DRB1*1301: A metaâ€enalysis of HLA–DRB1 associations with anti–citrullinated protein antibody–positive and anti–citrullinated protein antibody–negative rheumatoid arthritis in four European populations. Arthritis and Rheumatism, 2010, 62, 1236-1245.	6.7	135
49	Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1042-1055.	5.6	135
50	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	1.0	133
51	A new immunometabolic perspective of intervertebral disc degeneration. Nature Reviews Rheumatology, 2022, 18, 47-60.	8.0	131
52	Anti–Interleukinâ€6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis–Associated Uveitis Refractory to Anti–Tumor Necrosis Factor Therapy: A Multicenter Study of Twentyâ€Five Patients. Arthritis and Rheumatology, 2017, 69, 668-675.	5.6	129
53	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
54	Insulin resistance in rheumatoid arthritis: the impact of the anti‶NFâ€Î± therapy. Annals of the New York Academy of Sciences, 2010, 1193, 153-159.	3.8	125

#	Article	IF	Citations
55	Erythema nodosum: Etiologic and predictive factors in a defined population. Arthritis and Rheumatism, 2000, 43, 584.	6.7	123
56	Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations. Journal of Autoimmunity, 2010, 34, 155-162.	6.5	123
57	Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1764-1770.	0.9	123
58	Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Seminars in Arthritis and Rheumatism, 2018, 48, 22-27.	3.4	123
59	Relapses and Recurrences in Giant Cell Arteritis. Medicine (United States), 2011, 90, 186-193.	1.0	122
60	The High Prevalence of Subclinical Atherosclerosis in Patients With Ankylosing Spondylitis Without Clinically Evident Cardiovascular Disease. Medicine (United States), 2009, 88, 358-365.	1.0	121
61	Carotid Intima Media Thickness in Rheumatoid Arthritis as Compared to Control Subjects: A Meta-Analysis. Seminars in Arthritis and Rheumatism, 2011, 40, 389-397.	3.4	120
62	Adipokines and inflammation: is it a question of weight?. British Journal of Pharmacology, 2018, 175, 1569-1579.	5.4	119
63	Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases. Biochemical Pharmacology, 2019, 165, 196-206.	4.4	119
64	Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nature Reviews Rheumatology, 2012, 8, 224-234.	8.0	118
65	Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Seminars in Arthritis and Rheumatism, 2016, 46, 261-271.	3.4	118
66	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
67	Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Research and Therapy, 2011, 13, R101.	3.5	117
68	Henoch-Schönlein Purpura in Northern Spain. Medicine (United States), 2014, 93, 106-113.	1.0	117
69	TNFA â°'308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis, 2011, 216, 125-130.	0.8	116
70	Efficacy of Tocilizumab in Conventional Treatment–Refractory Adultâ€Onset Still's Disease: Multicenter Retrospective Open‣abel Study of Thirtyâ€Four Patients. Arthritis and Rheumatology, 2014, 66, 1659-1665.	5.6	115
71	Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 1170-1173.	0.9	115
72	Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Seminars in Arthritis and Rheumatism, 2015, 44, 717-723.	3.4	114

#	Article	IF	Citations
<b>7</b> 3	Comparative clinical and epidemiological study of hypersensitivity vasculitis versus Henoch-Schönlein purpura in adults. Seminars in Arthritis and Rheumatism, 1999, 28, 404-412.	3.4	113
74	Systemic Sclerosis in Northwestern Spain. Medicine (United States), 2008, 87, 272-280.	1.0	109
<b>7</b> 5	Anti-TNF-Â therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology, 2014, 53, 2223-2231.	1.9	109
76	Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. Autoimmunity Reviews, 2016, 15, 1013-1030.	5.8	107
77	A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Human Molecular Genetics, 2008, 18, 569-579.	2.9	106
78	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	2.9	104
79	Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Seminars in Arthritis and Rheumatism, 2004, 33, 231-238.	3.4	102
80	High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci. Annals of the Rheumatic Diseases, 2015, 74, e13-e13.	0.9	100
81	Shortâ€term improvement of endothelial function in rituximabâ€treated rheumatoid arthritis patients refractory to tumor necrosis factor α blocker therapy. Arthritis and Rheumatism, 2008, 59, 1821-1824.	6.7	98
82	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	2.9	98
83	Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?. Rheumatology, 2014, 53, 1108-1119.	1.9	98
84	Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Seminars in Arthritis and Rheumatism, 2016, 46, 71-80.	3.4	98
85	Endothelial Dysfunction, Carotid Intima-Media Thickness, and Accelerated Atherosclerosis in Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism, 2008, 38, 67-70.	3.4	96
86	Cardiovascular disease in inflammatory rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2016, 30, 851-869.	3.3	95
87	Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project. Seminars in Arthritis and Rheumatism, 2015, 44, 618-626.	3.4	94
88	Association of <i> STAT4 &lt; /i &gt; with rheumatoid arthritis: A replication study in three European populations. Arthritis and Rheumatism, 2008, 58, 1974-1980.</i>	6.7	93
89	Adult-onset Still's disease: Advances in the treatment. Best Practice and Research in Clinical Rheumatology, 2016, 30, 222-238.	3.3	91
90	Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis and Rheumatism, 2000, 43, 1749-1755.	6.7	89

#	Article	IF	Citations
91	Rheumatic Manifestations of Infective Endocarditis in Non-Addicts. Medicine (United States), 2001, 80, 9-19.	1.0	89
92	Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study. Rheumatology, 2018, 57, 856-864.	1.9	88
93	Effect of anti–tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis and Rheumatism, 2006, 55, 150-153.	6.7	86
94	Molecular Relationships among Obesity, Inflammation and Intervertebral Disc Degeneration: Are Adipokines the Common Link?. International Journal of Molecular Sciences, 2019, 20, 2030.	4.1	84
95	Giant Cell Arteritis: Epidemiology, Diagnosis, and Management. Current Rheumatology Reports, 2010, 12, 436-442.	4.7	83
96	Genetic component of giant cell arteritis. Rheumatology, 2014, 53, 6-18.	1.9	83
97	Audiovestibular Manifestations in Giant Cell Arteritis. Medicine (United States), 2003, 82, 13-26.	1.0	81
98	Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. American Journal of Ophthalmology, 2019, 200, 85-94.	3.3	81
99	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. Arthritis and Rheumatology, 2021, 73, 1073-1085.	5.6	81
100	Anti-TNF- $\hat{l}_{\pm}$ therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Seminars in Arthritis and Rheumatism, 2015, 45, 361-368.	3.4	78
101	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
102	Metabolic Syndrome in Rheumatoid Arthritis. Mediators of Inflammation, 2013, 2013, 1-11.	3.0	77
103	Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Seminars in Arthritis and Rheumatism, 2016, 46, 95-101.	3.4	77
104	Biomechanics, obesity, and osteoarthritis. The role of adipokines: When the levee breaks. Journal of Orthopaedic Research, 2018, 36, 594-604.	2.3	76
105	Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases. Arthritis and Rheumatology, 2019, 71, 2081-2089.	5.6	74
106	Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox. Annals of the Rheumatic Diseases, 2014, 73, 1281-1283.	0.9	73
107	Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations. Genome Medicine, 2018, 10, 97.	8.2	73
108	NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis, 2012, 224, 426-429.	0.8	72

#	Article	IF	CITATIONS
109	Genetics of immunoglobulin-A vasculitis (Henoch-SchĶnlein purpura): An updated review. Autoimmunity Reviews, 2018, 17, 301-315.	5.8	72
110	Risk Factors and Predictive Models of Giant Cell Arteritis in Polymyalgia Rheumatica. American Journal of Medicine, 1997, 102, 331-336.	1.5	71
111	A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R71.	3.5	71
112	Analysis of a Functional BTNL2 Polymorphism in Type 1 Diabetes, Rheumatoid Arthritis, and Systemic Lupus Erythematosus. Human Immunology, 2005, 66, 1235-1241.	2.4	70
113	<i>HO†</i> promoter polymorphism associated with rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3953-3958.	6.7	68
114	Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: Scientific evidence and expert opinion. Seminars in Arthritis and Rheumatism, 2014, 44, 1-8.	3.4	66
115	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Seminars in Arthritis and Rheumatism, 2019, 49, 126-135.	3.4	66
116	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Annals of the Rheumatic Diseases, 2020, 79, 988-990.	0.9	66
117	Cutaneous vasculitis as a paraneoplastic syndrome in adults. Arthritis and Rheumatism, 1998, 41, 1133-1135.	6.7	65
118	Prevalence of hepatitis C serum antibody in autoimmune diseases. Journal of Autoimmunity, 2009, 32, 261-266.	6.5	65
119	The <i>PTPN22</i> R263Q polymorphism is a risk factor for rheumatoid arthritis in Caucasian caseâ€"control samples. Arthritis and Rheumatism, 2011, 63, 365-372.	6.7	64
120	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.9	63
121	Relapses in patients with Henoch–Schönlein purpura. Medicine (United States), 2016, 95, e4217.	1.0	63
122	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. Seminars in Arthritis and Rheumatism, 2019, 48, 720-727.	3.4	63
123	Particle Repositioning Maneuver Versus Brandt-Daroff Exercise for Treatment of Unilateral Idiopathic BPPV of the Posterior Semicircular Canal. Otology and Neurotology, 2012, 33, 1401-1407.	1.3	62
124	A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Annals of the Rheumatic Diseases, 2015, 74, e15-e15.	0.9	62
125	Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Research, 2001, 3, 154.	2.0	61
126	A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. Journal of Rheumatology, 2005, 32, 1737-41.	2.0	61

#	Article	IF	CITATIONS
127	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	6.5	60
128	A combined large-scale meta-analysis identifies <i>COG6</i> as a novel shared risk <i>locus</i> for rheumatoid arthritis and systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2017, 76, 286-294.	0.9	58
129	Confirmation of <i>TNIP1 </i> <ii>but not <i>RHOB </i> <ii>and <i>PSORS1C1 </i> <ii>as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.</ii></ii></ii>	0.9	56
130	The Spectrum of Paraneoplastic Cutaneous Vasculitis in a Defined Population. Medicine (United) Tj ETQq0 0 0 rg	gBT_/Overlo	ock 10 Tf 50 6
131	Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clinical and Experimental Rheumatology, 2014, 32, S79-89.	0.8	55
132	Identification of a new putative functional IL18 gene variant through an association study in systemic lupus erythematosus. Human Molecular Genetics, 2009, 18, 3739-3748.	2.9	54
133	Systemic Lupus Erythematosus in Northwestern Spain. Medicine (United States), 2011, 90, 350-358.	1.0	54
134	Golimumab as Rescue Therapy for Refractory Immune-Mediated Uveitis: A Three-Center Experience. Mediators of Inflammation, 2014, 2014, 1-5.	3.0	54
135	Giant Cell Arteritis and Polymyalgia Rheumatica: an Update. Current Rheumatology Reports, 2015, 17, 6.	4.7	54
136	Analysis of RF5 gene functional polymorphisms in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 3815-3819.	6.7	53
137	Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: A prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis and Rheumatism, 2005, 53, 931-938.	6.7	52
138	Asymptomatic Hyperuricemia and Serum Uric Acid Concentration Correlate with Subclinical Atherosclerosis in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease11Drs. Gonzalez-Gay, Gonzalez-Juanatey, and Llorca contributed equally to this study Seminars in Arthritis and Rheumatism, 2009, 39, 157-162.	3.4	52
139	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.9	52
140	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
141	The Erythrocyte Sedimentation Rate Is Associated with the Development of Visual Complications in Biopsy-Proven Giant Cell Arteritis. Seminars in Arthritis and Rheumatism, 2008, 38, 116-123.	3.4	51
142	Antiâ€tumor necrosis factorâ€alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6â€month prospective study. Journal of Dermatology, 2016, 43, 1267-1272.	1.2	51
143	The diagnosis and management of patients with giant cell arteritis. Journal of Rheumatology, 2005, 32, 1186-8.	2.0	51
144	Study of functional variants of the <i>BANK1</i> gene in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 372-379.	6.7	50

#	Article	IF	CITATIONS
145	Anti-TNF-Alpha-Adalimumab Therapy Is Associated with Persistent Improvement of Endothelial Function without Progression of Carotid Intima-Media Wall Thickness in Patients with Rheumatoid Arthritis Refractory to Conventional Therapy. Mediators of Inflammation, 2012, 2012, 1-8.	3.0	50
146	HLA and non-HLA genes in Behçet's disease: a multicentric study in the Spanish population. Arthritis Research and Therapy, 2013, 15, R145.	3.5	50
147	Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease. Ophthalmology, 2018, 125, 1444-1451.	5.2	50
148	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Research and Therapy, 2006, 8, R109.	3.5	47
149	Association of a <i>CD24</i> gene polymorphism with susceptibility to systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 3080-3086.	6.7	47
150	Genetics of vasculitis. Current Opinion in Rheumatology, 2015, 27, 10-17.	4.3	47
151	Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review. Autoimmunity Reviews, 2021, 20, 102830.	5.8	47
152	Polymorphism of the MHC class II Eb gene determines the protection against collagen-induced arthritis. Immunogenetics, 1995, 42, 35-40.	2.4	46
153	Urticarial Vasculitis in Northern Spain. Medicine (United States), 2014, 93, 53-60.	1.0	46
154	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	5.8	46
155	Increased prevalence of subclinical atherosclerosis in patients with hidradenitis suppurativa (HS). Journal of the American Academy of Dermatology, 2016, 75, 329-335.	1.2	45
156	18 F-FDG PET/CT in the follow-up of large-vessel vasculitis: A study of 37 consecutive patients. Seminars in Arthritis and Rheumatism, 2018, 47, 530-537.	3.4	45
157	Acute febrile toxic reaction in patients with refractory rheumatoid arthritis who are receiving combined therapy with methotrexate and azathioprine. Arthritis and Rheumatism, 1996, 39, 1016-1020.	6.7	44
158	Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with Gout. Arthritis Care and Research, 2010, 62, 1299-1305.	3.4	44
159	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. Scientific Reports, 2017, 7, 5088.	3.3	44
160	IgA Vasculitis: Genetics and Clinical and Therapeutic Management. Current Rheumatology Reports, 2018, 20, 24.	4.7	44
161	Human leukocyte antigen-DRB1â^—1502 (DR2Dw12) transgene reduces incidence and severity of arthritis in mice. Human Immunology, 1996, 50, 54-60.	2.4	43
162	Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis and Rheumatism, 2004, 51, 274-277.	6.7	43

#	Article	IF	Citations
163	Cardiovascular disease inÂrheumatoid arthritis. Biomedicine and Pharmacotherapy, 2006, 60, 673-677.	5.6	43
164	Atherosclerosis in patients with biopsyâ€proven giant cell arteritis. Arthritis and Rheumatism, 2007, 57, 1481-1486.	6.7	43
165	Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases. Rheumatology, 2015, 54, 77-82.	1.9	42
166	IL-6: linking chronic inflammation and vascular calcification. Nature Reviews Rheumatology, 2019, 15, 457-459.	8.0	42
167	Fever in biopsy-proven giant cell arteritis: Clinical implications in a defined population. Arthritis and Rheumatism, 2004, 51, 652-655.	6.7	41
168	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. Journal of Clinical Rheumatology, 2011, 17, 349-355.	0.9	41
169	Giant Cell Arteritis: Visual Loss Is Our Major Concern. Journal of Rheumatology, 2016, 43, 1458-1461.	2.0	41
170	Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. Rheumatology International, 2007, 27, 927-933.	3.0	40
171	CCR5î"32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Research and Therapy, 2011, 13, R133.	3.5	40
172	SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R91.	3.5	40
173	Short-term improvement following dry needle stimulation of tender points in fibromyalgia. Rheumatology International, 2014, 34, 861-866.	3.0	40
174	Giant Cell Arteritis: A New Association with Benign Paroxysmal Positional Vertigo. Laryngoscope, 2004, 114, 1420-1425.	2.0	39
175	Clinical association between Kikuchi $\times^3$ s disease and systemic lupus erythematosus: A systematic literature review. Seminars in Arthritis and Rheumatism, 2017, 47, 46-52.	3.4	39
176	HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. Arthritis Research and Therapy, 2017, 19, 113.	<b>3.</b> 5	39
177	Audiovestibular Manifestations in Patients With Limited Systemic Sclerosis and Centromere Protein-B (CENP-B) Antibodies. Medicine (United States), 2008, 87, 131-141.	1.0	38
178	Lack of Echocardiographic and Doppler Abnormalities in Psoriatic Arthritis Patients Without Clinically Evident Cardiovascular Disease or Classic Atherosclerosis Risk Factors. Seminars in Arthritis and Rheumatism, 2006, 35, 333-339.	3.4	37
179	Tocilizumab for the treatment of adult-onset Still's disease. Expert Opinion on Biological Therapy, 2019, 19, 273-286.	3.1	37
180	Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clinical and Experimental Rheumatology, 2014, 32, S54-7.	0.8	37

#	Article	IF	CITATIONS
181	Association Between Toll-like Receptor 4 Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2009, 36, 1501-1506.	2.0	36
182	Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. Rheumatology International, 2013, 33, 2665-2670.	3.0	36
183	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatology International, 2016, 36, 1043-1063.	3.0	36
184	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	2.0	36
185	Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. Journal of Clinical Medicine, 2020, 9, 2816.	2.4	36
186	Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients. PLoS ONE, 2012, 7, e49214.	2.5	36
187	Aplasia Cutis Congenita in a Defined Population from Northwest Spain. Pediatric Dermatology, 2006, 23, 528-532.	0.9	35
188	Cancer in Biopsy-Proven Giant Cell Arteritis. A Population-Based Study. Seminars in Arthritis and Rheumatism, 2007, 37, 156-163.	3.4	35
189	Brief Report: Association of HLA–DRB1*01 With IgA Vasculitis (Henoch‣chönlein). Arthritis and Rheumatology, 2015, 67, 823-827.	5.6	35
190	Systemic and cerebral endothelial dysfunction in chronic migraine. A case-control study with an active comparator. Cephalalgia, 2016, 36, 552-560.	3.9	35
191	High triglycerides and low high-density lipoprotein cholesterol lipid profile in rheumatoid arthritis: A potential link among inflammation, oxidative status, and dysfunctional high-density lipoprotein. Journal of Clinical Lipidology, 2017, 11, 1043-1054.e2.	1.5	35
192	Giant Cell Arteritis and Polymyalgia Rheumatica. Drugs and Aging, 2006, 23, 627-649.	2.7	34
193	Carotid ultrasound in the cardiovascular risk stratification of patients with rheumatoid arthritis: when and for whom?. Annals of the Rheumatic Diseases, 2012, 71, 796-798.	0.9	34
194	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	2.0	34
195	Clinical spectrum time course of interstitial pneumonia with autoimmune features in patients positive for antisynthetase antibodies. Respiratory Medicine, 2017, 132, 265-266.	2.9	34
196	COVID â€19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain. Dermatologic Therapy, 2020, 33, e13961.	1.7	34
197	Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis. Mediators of Inflammation, 2012, 2012, 1-14.	3.0	33
198	Adipokines, Biomarkers of Endothelial Activation, and Metabolic Syndrome in Patients with Ankylosing Spondylitis. BioMed Research International, 2014, 2014, 1-11.	1.9	33

#	Article	IF	Citations
199	Association of HLA-B*41:02 with Henoch-Schönlein Purpura (IgA Vasculitis) in Spanish individuals irrespective of the HLA-DRB1 status. Arthritis Research and Therapy, 2015, 17, 102.	3.5	33
200	Efficacy of Anti-IL6-Receptor Tocilizumab in Refractory Cystoid Macular Edema of Birdshot Retinochoroidopathy Report of Two Cases and Literature Review. Ocular Immunology and Inflammation, 2017, 25, 609-614.	1.8	33
201	Interleukin 12 (IL12B) and Interleukin 12 Receptor (IL12RB1) Gene Polymorphisms in Rheumatoid Arthritis. Human Immunology, 2005, 66, 710-714.	2.4	32
202	Persistent Chronic Inflammation Contributes to the Development of Cancer in Patients with Rheumatoid Arthritis from a Defined Population of Northwestern Spain. Seminars in Arthritis and Rheumatism, 2007, 37, 31-38.	3.4	32
203	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Research and Therapy, 2012, 14, R85.	3.5	32
204	Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 429-436.	2.0	32
205	Sex differences in patients with systemic lupus erythematosus from Northwest Spain. Rheumatology International, 2014, 34, 11-24.	3.0	32
206	Drug-associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center. Journal of Rheumatology, 2014, 41, 2201-2207.	2.0	32
207	Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clinical and Experimental Rheumatology, 2016, 34, S44-53.	0.8	32
208	Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles. Autoimmunity Reviews, 2004, 3, 301-304.	<b>5.</b> 8	31
209	Deletion of LCE3C and LCE3B is a susceptibility factor for psoriatic arthritis: A study in Spanish and Italian populations and meta-analysis. Arthritis and Rheumatism, 2011, 63, 1860-1865.	6.7	31
210	Carotid plaques as predictors of cardiovascular events in patients with Rheumatoid Arthritis. Results from a 5-year-prospective follow-up study. Seminars in Arthritis and Rheumatism, 2020, 50, 1333-1338.	3.4	31
211	Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Seminars in Arthritis and Rheumatism, 2020, 50, 608-615.	3.4	31
212	HLA-B35 association with nephritis in Henoch-Schönlein purpura. Journal of Rheumatology, 2002, 29, 948-9.	2.0	31
213	Association between functional haplotypes of vascular endothelial growth factor and renal complications in Henoch-Schönlein purpura. Journal of Rheumatology, 2006, 33, 69-73.	2.0	31
214	Audiovestibular Manifestations in Patients With Ankylosing Spondylitis. Medicine (United States), 2011, 90, 99-109.	1.0	30
215	Assessment of cardiovascular risk in rheumatoid arthritis: impact of the new EULAR recommendations on the score cardiovascular risk index. Clinical Rheumatology, 2012, 31, 35-39.	2.2	30
216	Influence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet's disease. Human Immunology, 2013, 74, 230-233.	2.4	30

#	Article	IF	Citations
217	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.9	30
218	Epistatic Interaction of ERAP1 and HLA-B in Behçet Disease: A Replication Study in the Spanish Population. PLoS ONE, 2014, 9, e102100.	2.5	30
219	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project. Journal of Clinical Lipidology, 2017, 11, 749-756.e3.	1.5	30
220	Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatology, 2020, 59, 2847-2856.	1.9	30
221	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
222	<i>CARD8</i> rs2043211 (p.C10X) Polymorphism Is Not Associated with Disease Susceptibility or Cardiovascular Events in Spanish Rheumatoid Arthritis Patients. DNA and Cell Biology, 2013, 32, 28-33.	1.9	29
223	Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study. Arthritis Research and Therapy, 2015, 17, 55.	3.5	29
224	Paraoxonase 1 Activity Is Modulated by the rs662 Polymorphism and IgG Anti–Highâ€Đensity Lipoprotein Antibodies in Patients With Rheumatoid Arthritis: Potential Implications for Cardiovascular Disease. Arthritis and Rheumatology, 2016, 68, 1367-1376.	5.6	29
225	Serum Levels of Anti-PON1 and Anti-HDL Antibodies as Potential Biomarkers of Premature Atherosclerosis in Systemic Lupus Erythematosus. Thrombosis and Haemostasis, 2017, 117, 2194-2206.	3.4	29
226	Early large vessel systemic vasculitis in adults. Best Practice and Research in Clinical Rheumatology, 2019, 33, 101424.	3.3	29
227	Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology, 2020, 59, 1997-2004.	1.9	29
228	Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Crossâ€Sectional Study. Arthritis Care and Research, 2020, 72, 822-828.	3.4	28
229	Benign Paroxysmal Positional Vertigo and Clinical Test of Sensory Interaction and Balance in Systemic Sclerosis. Otology and Neurotology, 2008, 29, 1155-1161.	1.3	27
230	Cross-phenotype analysis of Immunochip data identifies <i>KDM4C</i> as a relevant <i>locus</i> for the development of systemic vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 589-595.	0.9	27
231	Evidence of New Risk Genetic Factor to Systemic Lupus Erythematosus: The UBASH3A Gene. PLoS ONE, 2013, 8, e60646.	2.5	27
232	Tubulointerstitial nephritis and uveitis syndrome in Southern Spain. Seminars in Arthritis and Rheumatism, 2002, 32, 125-129.	3.4	26
233	Deletion of the late cornified envelope genes, <i>LCE3C</i> and <i>LCE3B</i> , is associated with rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 1246-1251.	6.7	26
234	The ZC3HC1 rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2013, 15, R152.	3.5	26

#	Article	IF	CITATIONS
235	Osteoprotegerin Concentrations Relate Independently to Established Cardiovascular Disease in Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 39-45.	2.0	26
236	Giant cell arteritis: is the clinical spectrum of the disease changing?. BMC Geriatrics, 2019, 19, 200.	2.7	26
237	Identification of a 3′â€Untranslated Genetic Variant of <i>&gt;<scp>RARB</scp></i> Associated With Carotid Intimaâ€Media Thickness in Rheumatoid Arthritis: A Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2019, 71, 351-360.	5.6	26
238	Austrian syndrome: Report of two new cases and literature review. International Journal of Cardiology, 2006, 108, 273-275.	1.7	25
239	Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis Research and Therapy, 2010, 12, R51.	3.5	25
240	Vitamin D deficiency in chronic inflammatory rheumatic diseases: results of the cardiovascular in rheumatology [CARMA] study. Arthritis Research and Therapy, 2015, 17, 211.	3.5	25
241	Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients. Rheumatology International, 2015, 35, 2069-2078.	3.0	25
242	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39, 69-75.	0.8	25
243	Anomalies of vertebrae and ribs: Jarcho Levin syndrome. Description of a case and literature review. Joint Bone Spine, 2005, 72, 275-277.	1.6	24
244	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Annals of the Rheumatic Diseases, 2015, 74, e19-e19.	0.9	24
245	Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212368.	0.9	24
246	Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis. PLoS ONE, 2013, 8, e61044.	2.5	24
247	The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and Experimental Rheumatology, 2019, 37, 694-704.	0.8	24
248	Evidence of association of the <i> NLRP1 </i>   jene with giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 72, 628-630.	0.9	23
249	Marked Independent Relationship between Circulating Interleukin-6 Concentrations and Endothelial Activation in Rheumatoid Arthritis. Mediators of Inflammation, 2013, 2013, 1-10.	3.0	23
250	Lack of Association betweenABO,PPAP2B,ADAMST7,PIK3CG, andEDNRAand Carotid Intima-Media Thickness, Carotid Plaques, and Cardiovascular Disease in Patients with Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	23
251	Anakinra for the treatment of adult-onset Still's disease. Expert Review of Clinical Immunology, 2018, 14, 979-992.	3.0	23
252	An Update on the Role of Leptin in the Immuno-Metabolism of Cartilage. International Journal of Molecular Sciences, 2021, 22, 2411.	4.1	23

#	Article	IF	Citations
253	Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. Journal of Rheumatology, 2008, 35, 850-4.	2.0	23
254	Successful effect of tocilizumab in anti-TNF- $\hat{l}_{\pm}$ -induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine, 2012, 79, 510-513.	1.6	22
255	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation â€. Journal of Clinical Medicine, 2020, 9, 1606.	2.4	22
256	Inflammatory Arthritis and Heart Disease. Current Pharmaceutical Design, 2018, 24, 262-280.	1.9	22
257	Giant cell arteritis: Diagnosis and therapeutic management. Current Rheumatology Reports, 2006, 8, 299-302.	4.7	21
258	Localized Vasculitis of the Gastrointestinal Tract. Seminars in Arthritis and Rheumatism, 2006, 35, 403-406.	3.4	21
259	Association of acid phosphatase locus 1*C allele with the risk of cardiovascular events in rheumatoid arthritis patients. Arthritis Research and Therapy, 2011, 13, R116.	3.5	21
260	Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis. Atherosclerosis, 2011, 219, 655-658.	0.8	21
261	Lack of Association Between <i>TLR4</i> rs4986790 Polymorphism and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis. DNA and Cell Biology, 2012, 31, 1214-1220.	1.9	21
262	Study of six X-linked tetranucleotide microsatellites: population data from five Spanish regions. International Journal of Legal Medicine, 2006, 120, 147-150.	2.2	20
263	Evidence for <i>PTPN22</i> R620W Polymorphism As the Sole Common Risk Variant for Rheumatoid Arthritis in the 1p13.2 Region. Journal of Rheumatology, 2011, 38, 2290-2296.	2.0	20
264	Role of rs1343151 <i>IL23R</i> and rs3790567 <i>IL12RB2</i> Polymorphisms in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2011, 38, 889-892.	2.0	20
265	Obesity impairs efficacy of anti-TNF therapy in patients with RA. Nature Reviews Rheumatology, 2012, 8, 641-642.	8.0	20
266	Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients. Arthritis Research and Therapy, 2013, 15, R17.	3.5	20
267	Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206.	3.5	20
268	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opinion on Biological Therapy, 2020, 20, 717-723.	3.1	20
269	Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. Journal of Rheumatology, 2007, 34, 1535-9.	2.0	20
270	Influence of <i>CD40</i> rs1883832 Polymorphism in Susceptibility to and Clinical Manifestations of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2076-2080.	2.0	19

#	Article	IF	CITATIONS
271	Association of CD247 Polymorphisms with Rheumatoid Arthritis: A Replication Study and a Meta-Analysis. PLoS ONE, 2013, 8, e68295.	2.5	19
272	Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, R146.	3.5	19
273	The Framingham Score and the Systematic Coronary Risk Evaluation at Low Cutoff Values Are Useful Surrogate Markers of High-risk Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 486-494.	2.0	19
274	Atherosclerotic disease in axial spondyloarthritis: increased frequency of carotid plaques. Clinical and Experimental Rheumatology, 2015, 33, 315-20.	0.8	19
275	Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 465-473.	0.8	19
276	Leptin in Osteoarthritis and Rheumatoid Arthritis: Player or Bystander?. International Journal of Molecular Sciences, 2022, 23, 2859.	4.1	19
277	Orlistat-induced cutaneous leukocytoclastic vasculitis. Arthritis and Rheumatism, 2002, 47, 567-567.	6.7	18
278	Osteitis pubis after Marshall–Marchetti–Krantz urethropexy. Joint Bone Spine, 2003, 70, 61-63.	1.6	18
279	Human leukocyte antigen-DQB1 and -DRB1 associations in patients with idiopathic sudden sensorineural hearing loss from a defined population of Northwest Spain. Acta Oto-Laryngologica, 2005, 125, 1277-1282.	0.9	18
280	Analysis of the <i>REL</i> polymorphism rs13031237 in autoimmune diseases. Annals of the Rheumatic Diseases, 2011, 70, 711-712.	0.9	18
281	Inflammation, endothelial function and atherosclerosis in rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, 122.	3.5	18
282	Efficacy of a multidisciplinary treatment program in patients with severe fibromyalgia. Rheumatology International, 2012, 32, 2497-2502.	3.0	18
283	Cholesteryl Ester Transfer Protein in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1040-1047.	2.0	18
284	Investigations into Audiovestibular Manifestations in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2018-2026.	2.0	18
285	New insights into the pathogenesis of giant cell arteritis and hopes for the clinic. Expert Review of Clinical Immunology, 2016, 12, 57-66.	3.0	18
286	Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. Archives of Dermatological Research, 2020, 312, 595-600.	1.9	18
287	Rheumatoid arthritis related interstitial lung disease. Expert Review of Clinical Immunology, 2021, 17, 485-497.	3.0	18
288	Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review. Clinical and Experimental Rheumatology, 2014, 32, 864-8.	0.8	18

#	Article	lF	Citations
289	GIMAP and Behçet disease: no association in the European population: TableÂ1. Annals of the Rheumatic Diseases, 2014, 73, 1433-1434.	0.9	17
290	Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. Scientific Reports, 2018, 8, 8195.	3.3	17
291	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. Expert Review of Clinical Immunology, 2018, 14, 593-605.	3.0	17
292	Treatment of polymyalgia rheumatica. Biochemical Pharmacology, 2019, 165, 221-229.	4.4	17
293	Levels of the Novel Endogenous Antagonist of Ghrelin Receptor, Liver-Enriched Antimicrobial Peptide-2, in Patients with Rheumatoid Arthritis. Nutrients, 2020, 12, 1006.	4.1	17
294	Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients. Journal of Rheumatology, 2021, 48, 741-750.	2.0	17
295	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. PLoS ONE, 2014, 9, e113476.	2.5	17
296	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.8	17
297	Identification of the oxidative stress–related gene <i>MSRA</i> as a rheumatoid arthritis susceptibility locus by genomeâ€wide pathway analysis. Arthritis and Rheumatism, 2010, 62, 3183-3190.	6.7	16
298	Medical management of polymyalgia rheumatica. Expert Opinion on Pharmacotherapy, 2010, 11, 1077-1087.	1.8	16
299	Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis. Clinical Science, 2016, 130, 1889-1899.	4.3	16
300	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. Expert Review of Clinical Immunology, 2020, 16, 23-36.	3.0	16
301	Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. Journal of Clinical Medicine, 2020, 9, 3070.	2.4	16
302	Proprotein convertase subtilisin/kexin type 9 is related to disease activity and damage in patients with systemic erythematosus lupus. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097590.	2.7	16
303	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4098.	2.4	16
304	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. Journal of Clinical Medicine, 2021, 10, 3704.	2.4	16
305	Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. Clinical and Experimental Rheumatology, 2018, 36, 73-80.	0.8	16
306	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies. Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.8	16

#	Article	IF	Citations
307	Tocilizumab in Beh§et's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. Clinical and Experimental Rheumatology, 2021, 39, 37-42.	0.8	16
308	Systemic vasculitides. Best Practice and Research in Clinical Rheumatology, 2002, 16, 833-845.	3.3	15
309	CD4+CD25+ T Cell-Dependent Inhibition of Autoimmunity in Transgenic Mice Overexpressing Human Bcl-2 in T Lymphocytes. Journal of Immunology, 2007, 178, 2778-2786.	0.8	15
310	The clinical implication of cervical interspinous bursitis in the diagnosis of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2008, 67, 733-734.	0.9	15
311	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 2050-2052.	0.9	15
312	Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease. Current Pharmaceutical Design, 2014, 21, 182-201.	1.9	15
313	Biologic therapy in ANCA-negative vasculitis. International Immunopharmacology, 2015, 27, 213-219.	3.8	15
314	Treatment of giant cell arteritis. Biochemical Pharmacology, 2019, 165, 230-239.	4.4	15
315	Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective studyâ€"results at 5 years of follow-up. Rheumatology, 2021, 60, 2906-2915.	1.9	15
316	Biologic Therapy in COVID-19. Archivos De Bronconeumologia, 2021, 57, 1-2.	0.8	15
317	Analysis of Ancestral and Functionally Relevant CD5 Variants in Systemic Lupus Erythematosus Patients. PLoS ONE, 2014, 9, e113090.	2.5	15
318	Controversies on the Use of Corticosteroid Therapy in Children with Henoch-SchA¶nlein Purpura. Seminars in Arthritis and Rheumatism, 2005, 35, 135-137.	3.4	14
319	Association Study of <i>MIA3</i> rs17465637 Polymorphism with Cardiovascular Disease in Rheumatoid Arthritis Patients. DNA and Cell Biology, 2012, 31, 1412-1417.	1.9	14
320	Cutaneous Vasculitis: A Rheumatologist Perspective. Current Allergy and Asthma Reports, 2013, 13, 545-554.	5.3	14
321	Antitumour necrosis factor $\hat{l}_{\pm}$ treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases, 2014, 73, 941-943.	0.9	14
322	Kidney Function, Endothelial Activation and Atherosclerosis in Black and White Africans with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0121693.	2.5	14
323	Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 762-768.	0.9	14
324	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. Rheumatology, 2021, 60, 2801-2807.	1.9	14

#	Article	IF	Citations
325	Subclinical atherosclerotic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study on 806 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 395-403.	3.4	14
326	Bone mass and vitamin D in patients with systemic sclerosis from two Spanish regions. Clinical and Experimental Rheumatology, 2012, 30, 905-11.	0.8	14
327	Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clinical and Experimental Rheumatology, 2017, 35, 885-892.	0.8	14
328	The Increased Risk of Ventricular Diastolic Dysfunction and Congestive Heart Failure in Patients with Rheumatoid Arthritis Is Independent of the Duration of the Disease. Seminars in Arthritis and Rheumatism, 2005, 35, 132-133.	3.4	13
329	CXCL5 Gene Polymorphism Association with Diabetes Mellitus. Molecular Diagnosis and Therapy, 2008, 12, 391-394.	3.8	13
330	Replication of association of the interleukin 23 receptor rs1343151 variant with rheumatoid arthritis in Caucasian sample sets. Annals of the Rheumatic Diseases, 2012, 71, 155-157.	0.9	13
331	Association of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab Therapy. Journal of Osteoporosis, 2016, 2016, 1-6.	0.5	13
332	NSAIDs and cardiovascular risk in arthritis. Nature Reviews Cardiology, 2017, 14, 69-70.	13.7	13
333	New Criteria Needed for Antisynthetase Syndrome. JAMA Neurology, 2018, 75, 258.	9.0	13
334	Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus. Journal of Rheumatology, 2019, 46, 483-491.	2.0	13
335	Sex and Cardiovascular Involvement in Inflammatory Joint Diseases. Clinical Reviews in Allergy and Immunology, 2019, 56, 278-292.	6.5	13
336	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. Seminars in Arthritis and Rheumatism, 2021, 51, 387-394.	3.4	13
337	Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. Arthritis Research and Therapy, 2021, 23, 162.	3.5	13
338	The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39, 21-26.	0.8	13
339	Arthritis in the right great toe as the clinical presentation of tuberculosis. Arthritis and Rheumatism, 1998, 41, 374-375.	6.7	12
340	Analysis of the Interferon Gamma (rs2430561, +874T/A) Functional Gene Variant in Relation to the Presence of Cardiovascular Events in Rheumatoid Arthritis. PLoS ONE, 2012, 7, e47166.	2.5	12
341	The lp13.3 genomic region -rs599839- is associated with endothelial dysfunction in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R42.	3.5	12
342	SMAD3 rs17228212 Gene Polymorphism Is Associated with Reduced Risk to Cerebrovascular Accidents and Subclinical Atherosclerosis in Anti-CCP Negative Spanish Rheumatoid Arthritis Patients. PLoS ONE, 2013, 8, e77695.	2.5	12

#	Article	IF	Citations
343	Retinol-binding Protein 4 in Rheumatoid Arthritis-related Insulin Resistance and $\hat{l}^2$ -cell Function. Journal of Rheumatology, 2014, 41, 658-665.	2.0	12
344	Isolated pulmonary vasculitis: Case report and literature review. Seminars in Arthritis and Rheumatism, 2015, 44, 514-517.	3.4	12
345	Incretins in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 229.	3.5	12
346	Differences in Capacity of Highâ€Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 1590-1596.	3.4	12
347	Monomeric C reactive protein (mCRP) regulates inflammatory responses in human and mouse chondrocytes. Laboratory Investigation, 2021, 101, 1550-1560.	3.7	12
348	<i>HLA–B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	5 <b>.</b> 6	12
349	Diabetes mellitus and cardiovascular risk management in patients with rheumatoid arthritis: an international audit. RMD Open, 2021, 7, e001724.	3.8	12
350	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. Pharmaceuticals, 2021, 14, 819.	3.8	12
351	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	3.3	12
352	Interleukin 1 beta (IL $1 ilde{A}$ Ÿ) rs $16944$ genetic variant as a genetic marker of severe renal manifestations and renal sequelae in Henoch-Sch $ ilde{A}$ ¶nlein purpura. Clinical and Experimental Rheumatology, 2016, 34, S84-8.	0.8	12
353	Carotid ultrasound in the cardiovascular risk stratification of patients with ankylosing spondylitis: results of a population-based study. Clinical and Experimental Rheumatology, 2016, 34, 885-892.	0.8	12
354	Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review. Clinical and Experimental Rheumatology, 2018, 36, 652-657.	0.8	12
355	Optic Neuritis following Treatment with Isoniazid in a Hemodialyzed Patient. Nephron, 1993, 63, 360-360.	1.8	11
356	Benign Paroxysmal Positional Vertigo and Clinical Test of Sensory Interaction and Balance in Ankylosing Spondylitis. Otology and Neurotology, 2011, 32, 278-283.	1.3	11
357	Functional capacity in rheumatoid arthritis patients: comparison between Spanish and Brazilian sample. Rheumatology International, 2011, 31, 221-226.	3.0	11
358	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R154.	<b>3.</b> 5	11
359	Investigation of aPON1gene polymorphism (rs662 polymorphism) as predictor of subclinical atherosclerosis in patients with rheumatoid arthritis: TableÅ1. Annals of the Rheumatic Diseases, 2014, 73, 1749-1750.	0.9	11
360	Cardiovascular risk assessment according to a national calibrated score risk index in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Joint Bone Spine, 2014, 81, 164-168.	1.6	11

#	Article	IF	CITATIONS
361	Role of PTPN22 and CSK gene polymorphisms as predictors of susceptibility and clinical heterogeneity in patients with Henoch-Schã¶nlein purpura (IgA vasculitis). Arthritis Research and Therapy, 2015, 17, 286.	3.5	11
362	Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderateâ€toâ€severe psoriasis undergoing antiâ€tumor necrosis factorâ€Î± therapy. Journal of Dermatology, 2016, 43, 389-394.	1.2	11
363	Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis. Atherosclerosis, 2016, 245, 139-142.	0.8	11
364	Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2020, 47, 1344-1353.	2.0	11
365	Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models. Arthritis Research and Therapy, 2020, 22, 90.	3.5	11
366	Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project. Journal of Clinical Medicine, 2021, 10, 382.	2.4	11
367	Advances in the Treatment of Giant Cell Arteritis. Journal of Clinical Medicine, 2022, 11, 1588.	2.4	11
368	HLA-DRB1*04 may be a marker of severity in giant cell arteritis. Annals of the Rheumatic Diseases, 2000, 59, 574a-574.	0.9	10
369	Molecular screening and association study of IL15 gene polymorphisms in rheumatoid arthritis. Cytokine, 2007, 38, 84-89.	3.2	10
370	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Research and Therapy, 2012, 14, R273.	3.5	10
371	NPSR1 Gene Is Associated with Reduced Risk of Rheumatoid Arthritis. Journal of Rheumatology, 2012, 39, 1166-1170.	2.0	10
372	Antitumour necrosis factor- $\hat{l}_{\pm}$ therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients. Annals of the Rheumatic Diseases, 2013, 72, 1265-1267.	0.9	10
373	Relationship Between Insulin Sensitivity and $\hat{I}^2$ -Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 229-236.	2.0	10
374	Points to consider in cardiovascular disease risk management among patients with rheumatoid arthritis living in South Africa, an unequal middle income country. BMC Rheumatology, 2020, 4, 42.	1.6	10
375	Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. Journal of Rheumatology, 2021, 48, 339-347.	2.0	10
376	Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatology, 2021, 60, 2296-2306.	1.9	10
377	Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients. Biomedicines, 2021, 9, 847.	3.2	10
378	Osteoprotegerin CGA Haplotype Protection against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis. PLoS ONE, 2014, 9, e106823.	2.5	10

#	Article	IF	Citations
379	The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to BehA§et's disease: results of a multicentre open-label study. Clinical and Experimental Rheumatology, 2016, 34, S34-S40.	0.8	10
380	Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open, 2022, 8, e002103.	3.8	10
381	Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. Arthritis and Rheumatism, 1992, 35, 1249-1250.	6.7	9
382	<i>D</i> -Penicillamine-Induced Crescentic Glomerulonephritis in a Patient with Scleroderma. Nephron, 2000, 84, 101-102.	1.8	9
383	Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: Myth or reality?. Arthritis and Rheumatism, 2007, 57, 191-192.	6.7	9
384	C-Reactive Protein Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis from Northwestern Spain. Journal of Rheumatology, 2009, 36, 341-346.	2.0	9
385	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	2.0	9
386	Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis. Human Immunology, 2010, 71, 525-529.	2.4	9
387	Role of the CCR5/Δ32CCR5 polymorphism in biopsy-proven giant cell arteritis. Human Immunology, 2011, 72, 458-461.	2.4	9
388	Novel association of acid phosphatase locus 1*C allele with systemic lupus erythematosus. Human Immunology, 2012, 73, 107-110.	2.4	9
389	Lack of Association between <i>JAK3</i> Gene Polymorphisms and Cardiovascular Disease in Spanish Patients with Rheumatoid Arthritis. BioMed Research International, 2015, 2015, 1-11.	1.9	9
390	Cardiovascular risk factor assessment: still an unmet need in chronic inflammatory diseases. Heart, 2016, 102, 1937-1939.	2.9	9
391	Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?. Arthritis Research and Therapy, 2020, 22, 213.	3.5	9
392	Carotid ultrasound is useful for the cardiovascular risk stratification in patients with hidradenitis suppurativa. PLoS ONE, 2018, 13, e0190568.	2.5	9
393	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. Journal of Clinical Medicine, 2021, 10, 4975.	2.4	9
394	The Spanish version of the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for fibromyalgia: reliability and validity assessment. Clinical and Experimental Rheumatology, 2016, 34, S55-8.	0.8	9
395	Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 1013-1019.	0.8	9
396	Henoch-Schönlein purpura with hemorrhagic ascites and intestinal serositis. Gastrointestinal Endoscopy, 1996, 44, 624-625.	1.0	8

#	Article	IF	CITATIONS
397	Trends in the inflammatory response in biopsyâ€proven giant cell arteritis: Comment on the article by Cid et al, and the letters by Nesher and Sonnenblick and Liozon et al. Arthritis and Rheumatism, 2000, 43, 1427-1428.	6.7	8
398	Neovascularization around the optic nerve in giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 737-738.	6.7	8
399	Pacemaker infection due to Aspergillus: report of two cases and literature review. Clinical Cardiology, 2005, 28, 36-38.	1.8	8
400	Magnetic resonance imaging in optic neuritis due to giant cell arteritis. Arthritis and Rheumatism, 2005, 53, 313-314.	6.7	8
401	Multiple parosteal lipoma associated to polyarthritis. Joint Bone Spine, 2006, 73, 202-204.	1.6	8
402	Giant left atrial myxoma mimicking severe mitral valve stenosis. International Journal of Cardiology, 2008, 127, e110-e112.	1.7	8
403	Lack of Association Between <i>STAT4</i> Gene Polymorphism and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2009, 36, 1021-1025.	2.0	8
404	Lack of Association Between TRAF1/C5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 131-135.	2.0	8
405	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. Journal of Rheumatology, 2012, 39, 112-118.	2.0	8
406	Patients with Ankylosing Spondylitis and Low Disease Activity because of Anti-TNF-Alpha Therapy Have Higher TRAIL Levels Than Controls: A Potential Compensatory Effect. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	8
407	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	1.6	8
408	Beta-cell functionâ€,is disrupted in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 3826-3833.	1.9	8
409	Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk. Journal of Clinical Medicine, 2021, 10, 1671.	2.4	8
410	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. Journal of Clinical Medicine, 2021, 10, 2548.	2.4	8
411	An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 539-548.	3.0	8
412	QRISK3 relation to carotid plaque is higer than that of score in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 1408-1416.	1.9	8
413	Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open, 2021, 7, e001925.	3.8	8
414	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210932.	2.7	8

#	Article	IF	CITATIONS
415	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 2021, 39, 612-620.	0.8	8
416	Carotid intima-media thickness and endothelial function: useful surrogate markers for establishing cardiovascular risk in patients with inflammatory rheumatic disease. Arthritis Research and Therapy, 2008, 10, 403.	3.5	7
417	Atherosclerosis in Rheumatoid Arthritis. Mediators of Inflammation, 2012, 2012, 1-2.	3.0	7
418	Gene polymorphisms and therapy in rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 225-229.	3.3	7
419	Leveraging Genetic Findings for Precision Medicine in Vasculitis. Frontiers in Immunology, 2019, 10, 1796.	4.8	7
420	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. Seminars in Arthritis and Rheumatism, 2020, 50, 897-901.	3.4	7
421	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. Medicina (Lithuania), 2020, 56, 415.	2.0	7
422	Dickkopf-3 (DKK3) Signaling in IL-1α-Challenged Chondrocytes: Involvement of the NF-κB Pathway. Cartilage, 2020, , 194760352093332.	2.7	7
423	Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. Postepy Dermatologii I Alergologii, 2021, 38, 450-454.	0.9	7
424	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110209.	2.7	7
425	A Review of the Dermatological Complications of Giant Cell Arteritis. Clinical, Cosmetic and Investigational Dermatology, 2021, Volume 14, 303-312.	1.8	7
426	Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: a genetic and serological study. Arthritis Research and Therapy, 2021, 23, 111.	<b>3.</b> 5	7
427	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. Rheumatology, 2022, 61, 1204-1210.	1.9	7
428	Epidemiology of sarcoidosis in northern Spain, 1999-2019: A population-based study. European Journal of Internal Medicine, 2021, 91, 63-69.	2.2	7
429	Relationship of abdominal adiposity and body composition with endothelial dysfunction in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 516-23.	0.8	7
430	Serum cathepsin S and cystatin C: relationship to subclinical carotid atherosclerosis in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2016, 34, 230-5.	0.8	7
431	The angiopoietin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2022, 24, 99.	3.5	7
432	Potential role of mitral valve strands on stroke recurrence in rheumatoid arthritis. Arthritis and Rheumatism, 2003, 49, 866-867.	6.7	6

#	Article	IF	CITATIONS
433	Supraclavicular pulsatile mass as presenting sign of brachiocephalic trunk aneurysm in the long-term followup of giant cell arteritis. Arthritis and Rheumatism, 2005, 53, 475-476.	6.7	6
434	Two Polymorphisms in the Epithelial Cell-Derived Neutrophil-Activating Peptide (ENA-78) Gene. Disease Markers, 2005, 21, 75-77.	1.3	6
435	Lack of Association Between IRF5 Gene Polymorphisms and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 136-140.	2.0	6
436	Predictors of positive temporal artery biopsy in patients with giant cell arteritis and polymyalgia rheumatica (comment on the article by MarÃ-et al.). European Journal of Internal Medicine, 2010, 21, 51.	2.2	6
437	Refractory highly disfiguring lupus pernio: a dramatic and prolonged response to infliximab. International Journal of Dermatology, 2015, 54, e321-2.	1.0	6
438	Managing of giant cell arteritis and polymyalgia rheumatica. Expert Opinion on Orphan Drugs, 2016, 4, 1133-1144.	0.8	6
439	Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. Arthritis and Rheumatology, 2018, 70, 975-976.	5.6	6
440	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. Expert Opinion on Pharmacotherapy, 2018, 19, 1235-1244.	1.8	6
441	The role of biologics in the treatment of giant cell arteritis. Expert Opinion on Biological Therapy, 2019, 19, 65-72.	3.1	6
442	Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 3062.	2.4	6
443	Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis. Clinical and Experimental Rheumatology, 2010, 28, 31-4.	0.8	6
444	Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 241-9.	0.8	6
445	TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 491-7.	0.8	6
446	Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project. Clinical and Experimental Rheumatology, 2019, 37, 731-739.	0.8	6
447	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clinical and Experimental Rheumatology, 2022, 40, 142-149.	0.8	6
448	Factors associated with atherosclerosis in radiographic and non-radiographic axial spondyloarthritis. A multicenter study on 838 patients. Seminars in Arthritis and Rheumatism, 2022, 55, 152037.	3.4	6
449	H2-A polymorphism contributes to H2-Eβ-mediated protection in collagen-induced arthritis. Immunogenetics, 1996, 44, 377-384.	2.4	5
450	Rheumatoid Arthritis and Accelerated Atherogenesis. Circulation, 2004, 109, e328; author reply e328.	1.6	5

#	Article	IF	CITATIONS
451	Septic discitis as initial manifestation of streptococcus bovis endocarditis. International Journal of Cardiology, 2006, 108, 128-129.	1.7	5
452	Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis. Human Immunology, 2012, 73, 543-546.	2.4	5
453	IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy. BioMed Research International, 2014, 2014, 1-6.	1.9	5
454	The influence of inflammation in the development of subclinical atherosclerosis in psoriatic arthritis: comment on †Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review' by Jamnistki <i>et al</i> . Annals of the Rheumatic Diseases, 2014, 73, e27-e27.	0.9	5
455	Autoantibodies and biomarkers of endothelial cell activation in atherosclerosis. Vasa - European Journal of Vascular Medicine, 2014, 43, 83-85.	1.4	5
456	Enhanced Cardiovascular Risk in Rheumatoid Arthritis: Elucidation, Assessment, and Management. BioMed Research International, 2015, 2015, 1-3.	1.9	5
457	Relative Risk Chart Score for the Assessment of the Cardiovascular Risk in Young Patients with Ankylosing Spondylitis. International Journal of Rheumatology, 2018, 2018, 1-6.	1.6	5
458	Treating multidrugâ€resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the <scp>COVID</scp> â€19 pandemic. Dermatologic Therapy, 2020, 33, e14464.	1.7	5
459	Potential relation of cardiovascular risk factors to disease activity in patients with axial spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110337.	2.7	5
460	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. Expert Review of Clinical Immunology, 2021, 17, 225-232.	3.0	5
461	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. Scientific Reports, 2021, 11, 11510.	3.3	5
462	Henoch-Schönlein purpura (IgA vasculitis): the paradox of the different incidence and clinical spectrum in children and adults. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 3-4.	0.8	5
463	Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients. Clinical and Experimental Rheumatology, 2018, 36, 302-309.	0.8	5
464	Reclassification into very-high cardiovascular risk after carotid ultrasound in patients with axial spondyloarthritis. Clinical and Experimental Rheumatology, 2020, 38, 724-731.	0.8	5
465	Giant cell arteritis: more than a cranial disease. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 15-17.	0.8	5
466	Anti-IL-6 therapy reduces leptin serum levels in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 1201-1205.	0.8	5
467	Epidemiological and genetic features of anti-3â€'hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. European Journal of Internal Medicine, 2022, 101, 86-92.	2.2	5
468	Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2022, 13, .	4.8	5

#	Article	IF	Citations
469	Long-term rheumatoid arthritis and endothelial dysfunction. Atherosclerosis, 2004, 176, 197-198.	0.8	4
470	Contribution of HLA–DRB1 shared epitope alleles and chronic inflammation to the increased incidence of cardiovascular disease in rheumatoid arthritis: Comment on the article by Farragher et al. Arthritis and Rheumatism, 2008, 58, 2584-2584.	6.7	4
471	Role of asymptomatic hyperuricemia and serum uric acid levels in the pathogenesis of subclinical atherosclerosis in psoriatic arthritis: Comment on the article by Chen et al. Arthritis and Rheumatism, 2009, 61, 856-857.	6.7	4
472	Role of <i>BANK1</i> Gene Polymorphisms in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 1502-1504.	2.0	4
473	The Functional Polymorphism 844 A>G in Fcl+RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. Journal of Rheumatology, 2011, 38, 446-449.	2.0	4
474	A Nonsynonymous Functional Variant of the ITGAM Gene Is Not Involved in Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2011, 38, 2598-2601.	2.0	4
475	Autoimmune Rheumatic Diseases. BioMed Research International, 2014, 2014, 1-3.	1.9	4
476	Rituximab in Takayasu arteritis: an unmet hope. Rheumatology, 2018, 57, 1133-1134.	1.9	4
477	Genetic Basis of Vasculitides with Neurologic Involvement. Neurologic Clinics, 2019, 37, 219-234.	1.8	4
478	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. ReumatologÃa ClÃnica, 2022, 18, 33-41.	0.5	4
479	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	3.3	4
480	Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis. Clinical and Experimental Rheumatology, 2011, 29, S12-6.	0.8	4
481	Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population. Clinical and Experimental Rheumatology, 2012, 30, S29-33.	0.8	4
482	Lack of association between carotid intima-media wall thickness and carotid plaques and markers of endothelial cell activation in rheumatoid arthritis patients undergoing anti-TNF therapy. Acta Reumatol $\tilde{A}^3$ gica Portuguesa, 2012, 37, 155-9.	0.2	4
483	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.8	4
484	Subclinical atherosclerosis is not increased in patients with non-radiographic axial spondyloarthritis. Clinical and Experimental Rheumatology, 2016, 34, 159-60.	0.8	4
485	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. Clinical and Experimental Rheumatology, 2020, 38, 615-620.	0.8	4
486	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.8	4

#	Article	IF	CITATIONS
487	Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 69-75.	0.8	4
488	Utility of tocilizumab in autoimmune eye diseases. Expert Opinion on Biological Therapy, 2022, 22, 789-799.	3.1	4
489	Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease. Clinical and Translational Gastroenterology, 2022, 13, e00500.	2.5	4
490	Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis. Arthritis Research and Therapy, 2022, 24, .	3.5	4
491	Management of Cardiovascular Disease Risk in Rheumatoid Arthritis. Journal of Clinical Medicine, 2022, 11, 3487.	2.4	4
492	The pros and cons of intravenous immunoglobulin treatment in autoimmune nephropathy. Seminars in Arthritis and Rheumatism, 2004, 34, 573-574.	3.4	3
493	Influence of IL2RA rs2104286 Polymorphism in the Risk of Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 2331-2333.	2.0	3
494	Not losing sight is the issue in GCA management. Nature Reviews Rheumatology, 2010, 6, 440-441.	8.0	3
495	No evidence of association of the KLF12 gene with rheumatoid arthritis in Spanish and Dutch cohorts and a meta-analysis of published data. Human Immunology, 2011, 72, 779-782.	2.4	3
496	Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis. Journal of Rheumatology, 2012, 39, 1275-1279.	2.0	3
497	Etanercept-induced hypertriglyceridemia during the treatment of recurrent aphthous stomatitis. Indian Journal of Dermatology, Venereology and Leprology, 2013, 79, 432.	0.6	3
498	The search for improvement in the sensitivity of temporal artery biopsy in giant cell arteritis. Rheumatology, 2015, 54, 379-380.	1.9	3
499	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. PLoS ONE, 2018, 13, e0209343.	2.5	3
500	Misperception of the Cardiovascular Risk in Patients with Rheumatoid Arthritis. International Journal of Environmental Research and Public Health, 2020, 17, 5954.	2.6	3
501	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. Journal of Clinical Medicine, 2020, 9, 2608.	2.4	3
502	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. Journal of Rheumatology, 2021, 48, 1552-1558.	2.0	3
503	Role of VEGF Polymorphisms in the Susceptibility and Severity of Interstitial Lung Disease. Biomedicines, 2021, 9, 458.	3.2	3
504	Atypical presentation of immunoglobulin G4-related disease as subglottic stenosis: a case-based review. Rheumatology International, 2021, 41, 1161-1167.	3.0	3

#	Article	IF	Citations
505	Derrame pleural y pericárdico como única manifestación de enfermedad relacionada con IgG4. Archivos De Bronconeumologia, 2020, 56, 597-599.	0.8	3
506	"Silent―Giant Cell Arteritis. Southern Medical Journal, 2006, 99, 1204-1205.	0.7	3
507	Biologic therapy in refractory neurobehçet'sâ€,disease: a multicentre study of 41 patients and literature review. Rheumatology, 2022, 61, 4427-4436.	1.9	3
508	Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 171.	0.8	3
509	FGF23-Klotho axis in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 50-57.	0.8	3
510	Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 112-119.	0.8	3
511	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 21-26.	0.8	3
512	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. Biomedicines, 2022, 10, 851.	3.2	3
513	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics, 2021, 11, 2363.	2.6	3
514	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines. Clinical and Experimental Rheumatology, $0$ , , .	0.8	3
515	SCORE2 <i>versus </i> SCORE in patients with systemic lupus erythematosus. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210923.	2.7	3
516	WISP-2 modulates the induction of inflammatory mediators and cartilage catabolism in chondrocytes. Laboratory Investigation, 2022, 102, 989-999.	3.7	3
517	Treatment of migraine with monoclonal antibodies. Expert Opinion on Biological Therapy, 2022, 22, 707-716.	3.1	3
518	Apolipoprotein C-III in patients with systemic lupus erythematosus. Arthritis Research and Therapy, 2022, 24, 104.	3.5	3
519	The role of PET/CT in the evaluation of patients with large-vessel vasculitis: useful for diagnosis but with potential limitations for follow-up. Rheumatology, 2022, 61, 4587-4589.	1.9	3
520	Polymicrobial Prepatellar Septic Bursitis Caused by Brucella Abortus and Streptococcus Agalactiae. Journal of Clinical Rheumatology, 1997, 3, 120.	0.9	2
521	Anterior crural neuralgia as a presenting manifestation of lymphocele. Arthritis and Rheumatism, 2000, 43, 1183.	6.7	2
522	Fatigue fractures suggesting clinical monarthritis. Arthritis and Rheumatism, 2003, 49, 741-744.	6.7	2

#	Article	IF	CITATIONS
523	Re: Autoimmunity in sudden sensorineural hearing loss… by Cadoni et al. Acta Oto-Laryngologica, 2003, 123, 1115-1115.	0.9	2
524	Rheumatoid arthritis and anti-TNF-α therapy. Atherosclerosis, 2005, 181, 209.	0.8	2
525	Response to 'Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomized study over 21 months'. Arthritis Research and Therapy, 2011, 13, 404.	3.5	2
526	Interstitial Keratitis Secondary to Severe Hidradenitis Suppurativa Responding to Adalimumab. Cornea, 2012, 31, 206-206.	1.7	2
527	Association study of BAK1 gene polymorphisms in Spanish rheumatoid arthritis and systemic lupus erythematosus cohorts. Annals of the Rheumatic Diseases, 2012, 71, 314-316.	0.9	2
528	Lack of association between flow-mediated endothelium-dependent vasodilatation and biomarkers of endothelial dysfunction in patients with severe rheumatoid arthritis. Rheumatology International, 2012, 32, 4071-4072.	3.0	2
529	Brucellosis is not only responsible for monoarthritis but it is also associated with other osteoarticular complications. Rheumatology International, 2014, 34, 133-133.	3.0	2
530	Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases: comment on †Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative†by Baillet <i>et al</i>	0.9	2
531	Why is Rheumatoid Arthritis Mortality Still High Despite the Advent of New Therapies? Comment on the Article by Widdifield et al. Arthritis Care and Research, 2016, 68, 726-727.	3.4	2
532	Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis. Medicina ClÃnica, 2018, 151, 464-465.	0.6	2
533	Detection of high cardiovascular risk patients with ankylosing spondylitis based on the assessment of abdominal aortic calcium as compared to carotid ultrasound. Arthritis Research and Therapy, 2018, 20, 195.	3.5	2
534	Association of Human Leukocyte Antigens Class II Variants with Susceptibility to Hidradenitis Suppurativa in a Caucasian Spanish Population. Journal of Clinical Medicine, 2020, 9, 3095.	2.4	2
535	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4065.	2.4	2
536	Diagnóstico de la arteritis de células gigantes. Medicina ClÃnica, 2021, 157, 285-287.	0.6	2
537	Validation of the Spanish version of the fibromyalgia rapid screening tool to detect fibromyalgia in primary care health centres. Clinical and Experimental Rheumatology, 2016, 34, S125-8.	0.8	2
538	Amylin in the insulin resistance of patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2018, 36, 421-427.	0.8	2
539	Implication of CXCL5 (epithelial neutrophil-activating peptide 78) in the development of insulin resistance in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2019, 37, 373-379.	0.8	2
540	Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project. Clinical and Experimental Rheumatology, 2019, 37, 774-782.	0.8	2

#	Article	IF	Citations
541	Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 917-924.	0.8	2
542	The role of a functional variant of TYK2 in vasculitides and infections. Clinical and Experimental Rheumatology, 2020, 38, 949-955.	0.8	2
543	Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 69-75.	0.8	2
544	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. Clinical and Experimental Rheumatology, 2022, 40, 581-588.	0.8	2
545	Alpha-Klotho protein in systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	2
546	Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors. Clinical and Experimental Rheumatology, 2022, , .	0.8	2
547	Polymyalgia Rheumatica vs Rheumatoid Arthritis in the Elderly. Archives of Internal Medicine, 1997, 157, 2016.	3.8	1
548	Successful Response to Captopril in Severe Nephrotic Syndrome Secondary to Lupus Nephritis. Nephron, 1998, 80, 353-354.	1.8	1
549	Uncommon arthritis as presenting manifestation of silent Crohn's disease. Joint Bone Spine, 2000, 67, 553-554.	1.6	1
550	Lack of Association Between the rs6920220 (G/A) Polymorphism of the 6q23 Region and Biopsy-proven Giant Cell Arteritis. Journal of Rheumatology, 2010, 37, 1020-1023.	2.0	1
551	Subclinical Atherosclerosis in Ankylosing Spondylitis. Journal of Rheumatology, 2011, 38, 2073-2073.	2.0	1
552	Implication of new atherosclerotic carotid plaques in the cardiovascular outcome of patients with rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, 105.	3 <b>.</b> 5	1
553	Disparate results in studies of adalimumab in the treatment of hidradenitis suppurativa: comment on the article by Amano <i>etÂal</i> . International Journal of Dermatology, 2013, 52, 380-381.	1.0	1
554	Response to †Adipokines, inflammation, insulin resistance, and carotid atherosclerosis in patients with rheumatoid arthritis'. Arthritis Research and Therapy, 2014, 16, 401.	3.5	1
555	Is the Homeostatic Model Assessment of Insulin Resistance a Poor Predictor of Cardiovascular Disease in Rheumatoid Arthritis? Comment on the Article by Giles et al. Arthritis and Rheumatology, 2015, 67, 2548-2550.	<b>5.</b> 6	1
556	Positron emission tomography/computed tomography in relapsing polychondritis. Rheumatology, 2020, 59, 7-8.	1.9	1
557	O31â€Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
558	Gastrointestinal involvement in adult IGA vasculitis. Rheumatology, 2020, 59, 2659-2660.	1.9	1

#	Article	IF	Citations
559	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. Scientific Reports, 2021, 11, 16163.	3.3	1
560	Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opinion on Drug Safety, 2022, 21, 311-333.	2.4	1
561	QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine, 2021, 10, 4102.	2.4	1
562	Carotid ultrasound as predictor of atherosclerosis in rheumatoid arthritis. Vasa - European Journal of Vascular Medicine, 2012, 41, 311-312.	1.4	1
563	Molecular imaging in large vessel vasculitis has come to stay. Annals of Translational Medicine, 2018, 6, S2-S2.	1.7	1
564	Letter to the editor. Low-dose corticosteroids and blindness in giant cell arteritis. British Journal of Rheumatology, 1996, 35, 702-3.	2.3	1
565	Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients. Clinical and Experimental Rheumatology, 2016, 34, S93-7.	0.8	1
566	Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study. Clinical and Experimental Rheumatology, 2020, 38, 662-669.	0.8	1
567	Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
568	Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. Clinical and Experimental Rheumatology, 2021, 39 Suppl 132, 37-42.	0.8	1
569	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. Clinical and Experimental Rheumatology, 0, , .	0.8	1
570	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	1
571	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 0, , .	0.8	1
572	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 0, , .	0.8	1
573	Defining anti-synthetase syndrome: a systematic literature review Clinical and Experimental Rheumatology, 2022, 40, 309-319.	0.8	1
574	Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al. Arthritis and Rheumatism, 1996, 39, 1073-1074.	6.7	0
575	Can HLA-DR explain the varying frequency of synovitis in polymyalgia rheumatica? Comment on the article by Salvarani et al. Arthritis and Rheumatism, 1999, 42, 1561-1562.	6.7	0
576	Two coincidental neurological complications as a presenting form of infectious endocarditis. International Journal of Cardiology, 2007, 117, e107-e108.	1.7	0

#	Article	IF	CITATIONS
577	Role of carotid ultrasonography in the evaluation of cardiovascular risk in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, 409.	3.5	O
578	Cold Hands Associated with Scleroderma. New England Journal of Medicine, 2013, 369, 1638-1638.	27.0	0
579	Sex disparities in systemic lupus erythematosus in Northwestern Spain are not due to ethnic diversity. Rheumatology International, 2015, 35, 939-940.	3.0	O
580	Cardiovascular risk assessment in rheumatoid arthritis: What goals should be achieved?. Seminars in Arthritis and Rheumatism, 2015, 44, e20-e21.	3.4	0
581	Vitamina D y enfermedades reumÃ <sub>i</sub> ticas. ReumatologÃa ClÃnica, 2016, 12, 356-357.	0.5	0
582	Respuesta. Medicina ClÃnica, 2017, 148, e15-e16.	0.6	0
583	FRIO646â€EFFECT OF LONG-TERM MEDIUM-DOSE STEROID TREATMENT ON 18F-FDG PET/CT FINDINGS TO ASS VASCULAR AND MUSCULOESKELETAL INVOLVEMENT IN PATIENTSWITH POLYMYALGIA REUMATICA. , 2019, , .	ESS	0
584	AB1098â€COMPARISON OF THE PERFORMANCE OF CLASSIFICATION/DIAGNOSTIC CRITERIA FOR POLYMYALG RHEUMATICA. SINGLE CENTERSTUDY OF 100 PATIENTS. , 2019, , .	IA	0
585	SATO109â€SMOKING CESSATION IN PATIENTS WITH RA IS ASSOCIATED WITH REDUCED CVD EVENT RATES AN IMPROVED LIPID PROFILES AND PREDICTS LOWER RA DISEASE ACTIVITY. , 2019, , .	ID	O
586	FRIOO38â€HERPES ZOSTER IN RHEUMATOID ARTHRITIS. PROSPECTIVE SINGLE CENTER STUDY OF 390 RA PATIENTS FOR 5YEARS. , 2019, , .		0
587	OP0169â€LONG-TERM SURVIVAL IN LUNG TRANSPLANTATION FOR INTERSTITIAL LUNG DISEASE ASSOCIATED WITH CONECTIVE TISSUE DISEASES. STUDY OF 26 CASES OF A SINGLE CENTER. , 2019, , .		O
588	THU0566â€OCULAR FEATURES IN 381 PATIENTS WITH SYSTEMIC SARCOIDOSIS AND ITS CORRELATION WITH IWOS CRITERIA. STUDY IN A UNIVERSITY HOSPITAL. , 2019, , .	THE	0
589	SATO124â€MOLECULAR CHARACTERIZATION OF THE SERUM PROFILE ASSOCIATED TO THE INCREASED CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. EFFECTS OF BIOLOGICAL DRUGS, 2019, , .		O
590	THU0584â€RHEUMATOLOGICAL IMMUNE-RELATED ADVERSE EVENTS ASSOCIADTED WITH IMMUNOTHERAPY SOLID ORGAN TUMOR. STUDY OF 102 CASES FROM A REFERRAL SINGLE CENTER FOR LAST 4 YEARS. , 2019, , .	IN	0
591	Effect of cardiovascular disease on chronic inflammatory joint disease: reverse causality?. Expert Review of Clinical Immunology, 2020, 16, 855-858.	3.0	O
592	Comment on: Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity: reply. Rheumatology, 2021, 60, e268-e269.	1.9	0
593	Severe microscopic polyangiitis limited to the skin. Rheumatology, 2021, , .	1.9	0
594	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. Arthritis Research and Therapy, 2021, 23, 268.	3.5	0

#	Article	IF	CITATIONS
595	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. ReumatologÃa ClĀnica (English Edition), 2022, 18, 33-41.	0.3	0
596	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. Clinical and Experimental Rheumatology, 2013, 31, 186.	0.8	0
597	LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 208-209.	0.8	0
598	Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 166-170.	0.8	0
599	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 182-187.	0.8	0
600	Reply to: Comment on: Reclassification into very-high cardiovascular risk in psoriatic arthritis as well as axial spondyloarthritis. Clinical and Experimental Rheumatology, 2020, 38, 1268.	0.8	0
601	Association between homocysteine levels and arterial stiffness in women with systemic sclerosis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 92-97.	0.8	0
602	Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clinical and Experimental Rheumatology, 2021, 39, 612-620.	0.8	0
603	Coexisting sarcoidosis and systemic lupus erythematosus: a case report and literature review. Acta ReumatolA <sup>3</sup> gica Portuguesa, 2021, 46, 177-185.	0.2	0
604	Role of adiponectin in non-diabetic patients with rheumatoid arthritis undergoing anti-IL-6 therapy. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
605	Amylin serum levels are upregulated in patients with systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
606	Long-term survival of renal transplantation in patients with lupus nephritis: experience from a single university centre. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
607	Disease activity in patients with rheumatoid arthritis increases serum levels of apolipoprotein C-III. Clinical and Experimental Rheumatology, 2022, , .	0.8	O
608	Apolipoprotein C3 and beta-cell dysfunction are linked in patients with systemic lupus erythematosus Clinical and Experimental Rheumatology, 2021, , .	0.8	0
609	Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines Clinical and Experimental Rheumatology, 2022, , .	0.8	O
610	Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies Clinical and Experimental Rheumatology, 2022, 40, 274-283.	0.8	0
611	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype Clinical and Experimental Rheumatology, 2022, , .	0.8	0
612	Alpha-Klotho protein in systemic lupus erythematosus Clinical and Experimental Rheumatology, 2022,	0.8	0